Osteogenesis Imperfecta Types: Understanding Brittle Bone Disease

Imagine a child who fractures a bone simply by sneezing. A teenager who breaks a rib turning over in bed. A newborn whose bones shatter during delivery. These are not hypothetical extremes – they are the documented clinical realities of osteogenesis imperfecta, a genetic disorder so devastating in its severe forms that the term “brittle bone disease” barely captures what families living with it actually endure.

Yet for all its severity, osteogenesis imperfecta remains profoundly misunderstood – even in medical circles. Clinicians sometimes misdiagnose fractures as child abuse. Patients with milder forms go years without a formal diagnosis. And the broader public often conflates it with osteoporosis, a structurally and mechanistically different condition entirely.

This article provides a comprehensive clinical overview of osteogenesis imperfecta, covering its classification system, genetic mechanisms, systemic manifestations, diagnostic approach, current and emerging treatments, and the role of nutritional and integrative strategies in supporting skeletal resilience across the lifespan.

What Is Osteogenesis Imperfecta?

Osteogenesis imperfecta (OI) is a heritable connective tissue disorder characterized by bone fragility, low bone mass, and a predisposition to fractures from minimal trauma – or, in severe cases, no trauma at all. The name derives from the Latin: osteo (bone), genesis (formation), imperfecta (imperfect). Literally, it means “imperfect bone formation.”

Unlike osteoporosis, which is an acquired disease driven by hormonal change, aging, and lifestyle factors, OI is a genetic disorder present from conception. The bone architecture is intrinsically defective – not depleted by age but structurally compromised by a fault in the body’s fundamental protein manufacturing process.

OI occurs in approximately 1 in 10,000 to 20,000 live births worldwide, affecting males and females equally across all ethnic groups. It is considered the most common inherited bone fragility disorder in humans, and its range of clinical severity is extraordinary – from a mildly affected individual who sustains occasional fractures to one whose skeleton is so fragile that survival beyond birth is impossible.

The Collagen-1 Foundation: Why OI Is Not Simply “Weak Bones”

To understand osteogenesis imperfecta, you must first understand type I collagen – because OI is, at its molecular root, a type I collagen disorder.

Type I Collagen: The Architectural Scaffold of the Skeleton

Type I collagen is the most abundant structural protein in the human body. It forms the organic scaffold upon which bone is built – a triple-helix structure composed of two alpha-1 chains and one alpha-2 chain, encoded by the genes COL1A1 and COL1A2 respectively. Within bone, osteoblasts secrete procollagen, which is then assembled outside the cell into collagen fibrils. These fibrils provide the flexible tensile framework into which calcium and phosphate minerals are deposited – creating the composite material that makes bone simultaneously strong, flexible, and fracture-resistant.

Healthy bone is not simply hard tissue. It is a precisely engineered biocomposite: roughly 30% organic matrix (predominantly type I collagen) and 70% mineral content (hydroxyapatite). The collagen scaffold provides tensile flexibility – the property that allows bone to absorb impact without shattering. The mineral component provides compressive strength. When collagen is normal, bone bends before it breaks. When collagen is defective, it cannot absorb impact, and fracture results from forces that healthy bone would easily withstand.

As described in detail in the SVK Herbal article on tendinitis and connective tissue resilience, collagen is the foundational structural protein not only for bone but for tendons, ligaments, skin, corneas, and teeth – which is precisely why OI manifests across so many organ systems beyond the skeleton itself.

The Genetic Defects Behind OI

In approximately 85-90% of all OI cases, the causative mutation lies in the COL1A1 or COL1A2 genes. These mutations fall into two mechanistic categories:

Quantitative defects (COL1A1 haploinsufficiency): One copy of the COL1A1 gene is non-functional, reducing collagen type I production to approximately half the normal level. The collagen produced is structurally normal – there is simply less of it. This generally correlates with milder clinical presentations.

Qualitative (structural) defects: A mutation alters the amino acid sequence of the collagen chain, typically substituting glycine residues in the critical Gly-X-Y repeat sequence of the triple helix. Glycine is the only amino acid small enough to fit at the center of the triple helix; substituting it with a bulkier amino acid disrupts the entire helical structure. This structural disruption produces collagen fibers that are abnormally thin, disorganized, and mechanically inadequate – and typically correlates with more severe clinical forms of OI.

The remaining 10-15% of OI cases involve mutations in genes encoding proteins that support collagen biosynthesis, post-translational modification, or bone cell function. These forms – classified as Types V through XXI and beyond – follow autosomal recessive inheritance patterns and represent an expanding category as genomic medicine identifies new causative genes. Find out more about collagen’s role in bone density repair – essential context for understanding both OI pathophysiology and the therapeutic potential of collagen-based interventions.

The Sillence Classification: Understanding OI Types I Through IV

The most widely used clinical classification of osteogenesis imperfecta was developed by David Sillence in 1979 and remains the foundation of clinical communication. It defines four primary types based on clinical severity, radiographic findings, and inheritance pattern. These four classical types account for approximately 80-85% of all OI diagnoses.

Type I OI – Mild, Non-Deforming

Type I is the mildest and most common form of osteogenesis imperfecta, representing the majority of clinically diagnosed cases. It results from quantitative collagen deficiency – normal collagen produced in reduced quantities due to COL1A1 haploinsufficiency.

Key clinical features:

• Fracture frequency is elevated above the general population but rarely extreme; most fractures occur in childhood and reduce significantly after puberty
• Stature is typically normal or mildly short
• No significant skeletal deformity
• Blue sclerae – one of the most diagnostically recognizable features, caused by the thinness of the collagen-deficient sclera allowing the underlying choroid to show through
• Dentinogenesis imperfecta (brittle, discolored teeth) occurs in a subset of cases, designated Type Ib when present
• Progressive hearing loss occurs in approximately 50% of adult patients with Type I OI, typically beginning in the third or fourth decade of life due to otosclerosis affecting the middle ear ossicles
• Joint hypermobility and ligamentous laxity are common findings

Type I OI patients frequently live independently, participate in most activities, and may not receive a formal diagnosis until adulthood – particularly those without a family history. Many are initially evaluated for osteoporosis before the correct diagnosis is established.

Type II OI – Perinatally Lethal

Type II represents the most severe end of the osteogenesis imperfecta spectrum. It is uniformly lethal, with most affected individuals dying in utero or within days to weeks of birth from pulmonary insufficiency caused by a severely under-mineralized, deformed chest wall.

Key clinical features:

• Multiple intrauterine fractures detectable on prenatal ultrasound as early as the second trimester
• Profound skeletal under-mineralization
• Limb deformity, often severe and symmetrical
• Crumpled (“accordion”) femora on radiograph – a classic finding
• Extremely short limbs with significant bowing
• Soft, unmineralized calvarium
• Extremely small thorax, preventing adequate lung expansion

Type II OI results from de novo dominant mutations producing highly structurally disruptive collagen substitutions. Prenatal diagnosis via ultrasound identifies characteristic skeletal findings in severely affected fetuses, though confirmation requires molecular genetic testing. Genetic counseling is an essential component of care following a Type II diagnosis.

Type III OI – Progressively Deforming, Severe

Type III is the most severe non-lethal form of osteogenesis imperfecta – a distinction that carries significant clinical weight. These patients survive but face extraordinary physical challenges throughout their lives. Type III OI is characterized by progressive skeletal deformity, extremely short stature, and a very high lifetime fracture burden.

Key clinical features:

• Fractures beginning at or before birth (intrauterine fractures are common)
• Extremely short stature, with adult height rarely exceeding 3.5 feet
• Progressive, severe spinal deformity including scoliosis and kyphosis
• Progressive bowing of long bones from repeated fractures and abnormal healing
• White or grey sclerae in adulthood (bluish at birth, fading with age)
• Dentinogenesis imperfecta is nearly universal
• Basilar invagination – upward displacement of the skull base into the brain – occurs in a significant minority and can be life-threatening
• Pulmonary complications from thoracic deformity
• Most patients require wheelchair mobility by adulthood

Type III OI demands lifelong, multidisciplinary care involving orthopedic surgery, physiotherapy, pulmonology, and pain management. The emotional and psychological burden on patients and caregivers is substantial, and psychosocial support is a clinically recognized component of comprehensive OI management. The role of anti-inflammatory nutrition in supporting tissue quality and reducing the inflammatory cascades associated with repeated fracture and surgical intervention is an increasingly recognized adjunct in OI care.

Type IV OI – Moderate, Variable Severity

Type IV is the most clinically heterogeneous OI type – a classification that in some ways functions as a “catch-all” for dominant OI cases that are more severe than Type I but do not meet the criteria for Type III. Its clinical presentation spans a broad range.

Key clinical features:

• Moderate fracture frequency, typically reducing after puberty but often continuing into adulthood
• Mild to moderate short stature
• Variable skeletal deformity, usually less severe than Type III
• White or normal sclerae – a key distinguishing feature from Types I and II
• Dentinogenesis imperfecta occurs in approximately half of cases (designated Type IVb when present)
• Scoliosis and kyphosis are common but generally less severe than in Type III
• Hearing loss occurs but at lower frequency than in Type I

Many Type IV patients achieve ambulatory independence and, with appropriate medical management and orthopedic intervention, can maintain relatively active lives. However, chronic pain, fatigue, and the psychological impact of visible deformity or visible difference require ongoing attention alongside medical management.

Beyond the Classical Types: The Expanding OI Spectrum (Types V-XXI+)

Since 2000, advances in molecular genetics have dramatically expanded the OI classification landscape. Mutations in more than 20 different genes have now been identified as causative, each representing a distinct pathogenic mechanism affecting collagen synthesis, processing, secretion, or the broader osteoblast function.

Type V OI – Hyperplastic Callus Formation

Type V is caused by a mutation in the IFITM5 gene and is unique among OI types in its mechanism – it does not directly involve type I collagen genes. Its hallmark is the formation of hyperplastic callus: exuberant, calcified mass around fracture sites that can be clinically and radiographically alarming, mimicking sarcoma. Calcification of the interosseous membrane between the radius and ulna, limiting forearm rotation, is another characteristic finding. White sclerae and no dentinogenesis imperfecta. This type follows autosomal dominant inheritance.

Type VI OI – Mineralization Defect

Type VI is caused by mutations in SERPINF1, encoding pigment epithelium-derived factor (PEDF). It presents with moderate to severe bone fragility but uniquely shows a mineralization defect visible on bone biopsy, where unmineralized osteoid accumulates in a “fish scale” pattern. This type is refractory to bisphosphonate therapy in many cases, making correct genetic diagnosis clinically important for treatment planning.

Types VII-XXI and Beyond

Each progressively numbered OI type corresponds to a distinct genetic mutation affecting the collagen biosynthetic pathway:

• Type VII (CRTAP mutation) and Type VIII (LEPRE1/P3H1 mutation): Involve defects in collagen prolyl 3-hydroxylation – a post-translational modification essential for correct triple helix assembly. Often very severe.
• Type IX (PPIB mutation): Affects the peptidyl-prolyl isomerase cyclophilin B, another chaperone for collagen folding.
• Type X (SERPINH1 mutation) and Type XI (FKBP65/FKBP10 mutation): Involve collagen chaperone proteins essential for correct intracellular folding and transport.
• Type XII (SP7/Osterix mutation): Affects osteoblast transcription factor Osterix, impairing bone formation at the cellular level.
• Types XIII-XXI: Involve genes encoding additional components of osteoblast differentiation, WNT signaling pathways, bone matrix secretion, and intracellular calcium regulation.

The clinical implication of this expanding spectrum is significant: not all OI is the same, and not all OI responds to the same treatments. Genetic testing is no longer an academic luxury but a clinical necessity for optimal management.

Systemic Manifestations Beyond the Skeleton

Osteogenesis imperfecta is a systemic connective tissue disorder. Because type I collagen is present throughout the body, its deficiency or structural disruption affects multiple organ systems in ways that are often undertreated.

Dentinogenesis Imperfecta

Dentinogenesis imperfecta affects the dentin layer of teeth, producing characteristic grey-blue to amber discoloration, early loss of enamel, and progressive wearing of tooth surfaces. It occurs in Types I (subtype b), III, IV, and several rarer forms. Severe cases require early and aggressive dental management to preserve function and prevent complete tooth loss.

Hearing Loss

Progressive sensorineural and conductive hearing loss affects a significant minority of OI patients across types. The conductive component is caused by otosclerosis – abnormal bone remodeling affecting the ossicles of the middle ear. The sensorineural component reflects inner ear involvement. Audiological screening should be part of annual OI care across all types, beginning in childhood and continuing through adulthood.

Cardiovascular and Pulmonary Complications

In severe OI, thoracic deformity from multiple rib fractures and spinal scoliosis can progressively compromise respiratory function. Pulmonary complications are among the leading causes of mortality in adults with Types III and IV OI. Cardiac valvular regurgitation – most commonly aortic regurgitation – occurs with increased frequency in OI patients due to collagen deficiency in cardiac valve structures. Regular cardiorespiratory monitoring is an essential but often overlooked component of OI care.

Neurological Complications

Basilar invagination – progressive upward migration of the cervical spine into the skull base – occurs primarily in severe OI and can compress the brainstem, causing headache, balance disturbance, and in severe cases, potentially fatal neurological compromise. Regular cranial imaging is indicated for patients with Type III OI and for any patient with unexplained neurological symptoms.

Skin, Joints, and Eyes

Skin fragility and easy bruising reflect dermal collagen deficiency. Joint hypermobility from ligamentous laxity is common across OI types, contributing to joint pain and instability. Blue sclerae – caused by collagen-thin sclera allowing the underlying choroid vasculature to show through – remain one of the most clinically recognizable diagnostic features, though their presence and intensity varies by type and age. Find out more about joint health supplements that support collagen-dependent connective tissue in conditions of structural collagen vulnerability.

Diagnosis: How Osteogenesis Imperfecta Is Identified

Diagnosing OI requires clinical awareness, radiographic assessment, and increasingly, molecular genetic confirmation.

Clinical Diagnosis

The clinical triad of increased fracture frequency, blue sclerae, and dentinogenesis imperfecta is highly suggestive in the appropriate context. However, many patients – particularly those with Type I OI – present without all three features. One of the most important diagnostic pitfalls in OI is misdiagnosis as non-accidental injury (child abuse), which has led to wrongful investigations and family separations. Clinicians evaluating children with multiple unexplained fractures must rigorously consider OI before concluding abuse.

Radiographic Assessment

Characteristic radiographic findings include:

• Generalized osteopenia (reduced bone density on plain film)
• Wormian bones – small, irregular ossicles within the cranial sutures, detectable on skull X-ray
• Cortical thinning of long bones
• Evidence of healed or healing fractures at multiple sites and ages
• In severe forms: bowing of long bones, vertebral compression fractures, scoliosis, and the characteristic “crumpled” appearance of perinatally lethal cases

Dual-energy X-ray absorptiometry (DXA) is used to quantify bone mineral density, though standard DXA Z-scores may underestimate skeletal compromise in OI due to body size effects that are not fully corrected by standard normative data.

Genetic Testing

Molecular genetic testing of COL1A1 and COL1A2 confirms the diagnosis in approximately 85-90% of cases. Expanded gene panels covering the full spectrum of OI-associated genes are now available commercially and through academic medical centers. Genetic confirmation is essential for prognosis, family counseling, and increasingly for selecting the most appropriate treatment approach, particularly for rarer forms with gene-specific treatment responses.

Differential Diagnosis

Conditions to distinguish from OI include:

• Rickets and osteomalacia – impaired bone mineralization due to Vitamin D or phosphate deficiency, not collagen defect
• Idiopathic juvenile osteoporosis – low bone density without identifiable genetic cause
• Ehlers-Danlos syndrome – connective tissue disorder with overlapping features (joint hypermobility, skin fragility) but distinct genetic etiology
• Child abuse – multiple fractures without collagen pathology; clinical and radiographic differentiation is essential
• Hypophosphatasia – metabolic bone disease caused by alkaline phosphatase deficiency

Medical Management of Osteogenesis Imperfecta

There is currently no cure for OI. Medical management focuses on reducing fracture frequency, maintaining bone density, managing pain, preventing deformity, and maximizing functional independence.

Bisphosphonate Therapy

Bisphosphonates are the most widely used pharmacological intervention in OI, primarily intravenous pamidronate or zoledronic acid. By inhibiting osteoclast-mediated bone resorption, they increase bone mineral density and have been shown to reduce fracture rates in pediatric OI. Response is most robust in types with quantitative collagen deficiency (Type I) and more variable in structurally defective collagen types. Long-term use in children requires careful monitoring for jaw osteonecrosis and atypical femoral fractures, though these risks are substantially lower in pediatric patients than in adults.

Surgical Intervention – Intramedullary Rodding

Intramedullary (IM) rodding – surgically inserting flexible or telescoping metal rods through the medullary canal of long bones – is the primary surgical intervention for OI. Telescoping rods that elongate as the bone grows have significantly improved outcomes for pediatric patients with Sillence Types III and IV, reducing deformity progression and maintaining ambulatory function. Spinal surgery for scoliosis management is a major undertaking in OI patients due to the complexity of operating on structurally deficient bone.

Emerging Biological Therapies

The OI treatment landscape is rapidly evolving beyond bisphosphonates:

• Antisclerostin antibodies (romosozumab): Promote bone formation by inhibiting sclerostin, a suppressor of the WNT signaling pathway that drives osteoblast activity. Early trials show promise in OI.
• Anti-TGF-β therapy: TGF-β signaling is dysregulated in OI, contributing to aberrant bone remodeling. Fresolimumab and similar agents are in early clinical investigation.
• Mesenchymal stem cell (MSC) transplantation: Transplanted MSCs can differentiate into osteoblasts and produce normal type I collagen, potentially correcting the cellular defect. In utero MSC transplantation for severe prenatal OI is currently in clinical trial.
• Gene therapy and gene editing: Silencing the mutant COL1A1 or COL1A2 allele while preserving the normal allele is technically achievable in cell culture and animal models. Human trials are in early stages.

Physical and Rehabilitation Medicine

Physical therapy is not optional in OI management – it is central to it. Aquatic therapy is particularly valuable, providing resistance training and proprioceptive challenge without the fracture risk of land-based impact loading. For patients capable of weight-bearing, low-impact progressive loading following the principles of Wolff’s Law – that bone adapts to the mechanical demands placed upon it – is systematically applied. As explored in the Naturem article on yoga and weightlifting for skeletal longevity, isometric loading strategies that stimulate bone remodeling without high-impact shear forces are clinically well-suited to fragility conditions like OI.

Nutritional and Integrative Support in OI: What Does the Evidence Show?

While no nutritional intervention can correct a collagen gene mutation, the biochemical environment in which bone remodeling occurs can be meaningfully optimized through diet. Several specific nutritional targets are directly relevant to OI management.

Vitamin D and Calcium

Both are prerequisites for bone mineralization. In OI, the collagen scaffold is already defective – but ensuring that the mineral component is optimally deposited within it is a modifiable goal. Vitamin D supplementation is recommended for all OI patients who are not achieving adequate sun exposure, particularly in low-sunlight regions and for those with mobility limitations that restrict outdoor activity.

Vitamin C and Collagen Synthesis

Vitamin C is an essential cofactor for the enzymes prolyl hydroxylase and lysyl hydroxylase, which catalyze the post-translational hydroxylation reactions required for correct collagen triple helix formation and cross-linking. While OI patients produce defective collagen regardless of vitamin C status, adequate vitamin C ensures that the non-mutant collagen chains are hydroxylated and cross-linked as efficiently as possible. Vitamin C deficiency in OI would compound an already compromised collagen system – a clinically unnecessary insult that is entirely preventable through diet.

Foods richest in vitamin C – guava, kiwi, citrus, red bell pepper, papaya, and broccoli – should be consistently prioritized in the diets of OI patients of all ages.

Collagen Peptide Supplementation

Hydrolyzed collagen peptides have emerged as a clinically interesting adjunct in connective tissue conditions. As described in the Naturem Joints+ clinical overview, bioavailable collagen peptides – particularly those derived through advanced hydrolysis processes – are absorbed intact from the gastrointestinal tract and transported to connective tissues where they stimulate fibroblast and osteoblast activity. They appear to provide substrate and signaling stimulus for new collagen synthesis.

In OI specifically, where endogenous collagen production is either insufficient or structurally defective, collagen peptide supplementation is a biologically rationale adjunct. It cannot correct the genetic defect, but it may support the non-mutant collagen-producing pathways, enhance overall bone matrix density, and contribute to connective tissue quality in skin, tendons, and ligaments. The Naturem Joints+ formula explicitly includes OI among its target conditions, based on the US-patented hydrolyzed crocodile bone collagen peptide’s demonstrated bioavailability and bone-supportive profile.

Drynaria Fortunei: The Traditional Bone Herb

Drynaria Fortunei (Gu Sui Bu in Traditional Chinese Medicine) – one of the primary active ingredients in Naturem Joints+ – has been used for centuries in East Asian traditional medicine specifically for fracture healing, bone fragility, and bone loss. Its active compounds include naringin and flavonoids that stimulate osteoblast differentiation and activity, promote calcium retention in bone, and maintain tendon and ligament integrity. In the context of OI, where repeated fractures and deficient bone remodeling are central challenges, Drynaria’s osteoblast-stimulating properties represent a compelling traditional-medicine approach to supporting bone repair between fractures.

Anti-Inflammatory Diet Principles

OI patients undergo frequent fractures, surgical procedures, and periods of immobility – all of which generate systemic inflammatory burden. A dedicated anti-inflammatory dietary approach, emphasizing omega-3 fatty acids, polyphenol-rich vegetables and fruits, and minimal ultra-processed food, can meaningfully reduce chronic low-grade inflammation that impairs tissue healing and bone remodeling. Hydroxytyrosol from olive oil – a potent phenolic antioxidant with documented anti-osteoporotic effects including enhanced osteoblast activity and reduced osteoclast differentiation – is a nutritionally accessible compound of particular relevance to bone health in conditions of skeletal fragility.

Living with OI: Quality of Life, Psychological Impact, and Long-Term Prognosis

The lived experience of osteogenesis imperfecta is profoundly shaped by its type and severity. A person with Type I OI may live an essentially normal life with precautions. A person with Type III OI faces a lifetime of surgical interventions, chronic pain, mobility limitations, and the complex psychosocial dynamics of visible physical difference.

Chronic Pain Management

Chronic pain is under-recognized in OI and affects a substantial proportion of patients across all severity types. Pain arises from multiple sources: acute fractures, surgical recovery, deformity-related musculoskeletal stress, and central sensitization from years of repeated tissue injury. A comprehensive pain management approach integrates pharmacological management, physical therapy, psychological support, and complementary approaches including herbal anti-inflammatory formulations validated for musculoskeletal pain.

Transition to Adult Care

OI has historically been managed primarily as a pediatric condition. But adults with OI require continued specialist care – for bisphosphonate monitoring, cardiovascular and pulmonary surveillance, pain management, and psychological support. The transition from pediatric to adult OI services is a recognized gap in many healthcare systems globally.

Prognosis and Lifespan

Type I OI carries a near-normal life expectancy with appropriate management. Types III and IV are associated with elevated mortality risk primarily from pulmonary and neurological complications, though advances in medical and surgical management have substantially improved outcomes over the past three decades. Type II remains uniformly lethal at or shortly after birth.

Conclusion: A Complex Disease Demanding Comprehensive, Lifelong Care

Osteogenesis imperfecta is not a single disease but a spectrum – from the mildly affected adult who fractures infrequently to the child who requires surgical intervention repeatedly throughout childhood, to the newborn for whom survival is impossible. What unifies this spectrum is a shared molecular pathology: defective type I collagen that robs the skeleton of its tensile resilience.

The implications extend far beyond broken bones. OI affects teeth, ears, eyes, heart, lungs, and the central nervous system – a multisystem disease that demands multidisciplinary care across every stage of life. Advances in molecular genetics have dramatically expanded our understanding of the disease, identifying more than 20 distinct genetic subtypes and opening the door to targeted biological therapies that address the disease at its root.

For patients, families, and clinicians navigating OI, the evidence increasingly points to the same integrative principle that guides modern musculoskeletal medicine: the best outcomes arise when pharmacological intervention, surgical expertise, physical rehabilitation, nutritional optimization, and psychological support are combined deliberately and consistently. No single intervention is sufficient. But together, they build the most resilient possible life on the foundation of a fragile skeleton.

This article is intended for educational purposes only and does not constitute individual medical advice. Patients with osteogenesis imperfecta should be managed by a multidisciplinary specialist team with expertise in rare skeletal dysplasias. Do not modify medical treatment based on this article without physician guidance.

Frequently Asked Questions (FAQs)

References:

Baldridge, D., Schwarze, U., Morello, R., Lennington, J., Bertin, T. K., Pace, J. M., Pepin, M. G., Weis, M., Eyre, D., Walsh, J., Lambert, D., Green, A., Robinson, H., Michelson, M., Houge, G., Lindman, C., Martin, J., Ward, J., Lemyre, E., … Lee, B. (2008). CRTAP and LEPRE1 mutations in recessive osteogenesis imperfecta. Human Mutation, 29(12), 1435-1442.

Deguchi, M., Tsuji, S., Katsura, D., Kasahara, K., Kimura, F., & Murakami, T. (2021). Current overview of osteogenesis imperfecta. Medicina, 57(5), 464. https://doi.org/10.3390/medicina57050464

Dhage, P. P., & Wadhokar, O. C. (2022). Brittle bone disease (osteogenesis imperfecta): A rare condition. The Pan African Medical Journal, 43, 11. https://doi.org/10.11604/pamj.2022.43.11.35300

Indermaur, M., Casari, D., Kochetkova, T., Peruzzi, C., Zimmermann, E., Rauch, F., Willie, B., Michler, J., Schwiedrzik, J., & Zysset, P. (2021). Compressive strength of iliac bone ECM is not reduced in osteogenesis imperfecta and increases with mineralization. Journal of Bone and Mineral Research, 36(8), 1564-1575. https://doi.org/10.1002/jbmr.4286

Keupp, K., Beleggia, F., Kayserili, H., Barnes, A. M., Steiner, M., Semler, O., Fischer, B., Yigit, G., Janda, C. Y., Becker, J., Breer, S., Altunoglu, U., Grünhagen, J., Krawitz, P., Hecht, J., Schinke, T., Makareeva, E., Lausch, E., Cankaya, T., … Wollnik, B. (2013). Mutations in WNT1 cause different forms of bone dysplasia. American Journal of Human Genetics, 92(4), 565-574.

Lindert, U., Gnoli, M., Maioli, M., Bedeschi, M. F., Sangiorgi, L., Rohrbach, M., & Giunta, C. (2017). Insight into the pathology of a COL1A1 signal peptide heterozygous mutation leading to severe osteogenesis imperfecta. Calcified Tissue International, 102(4), 373-383. https://doi.org/10.1007/s00223-017-0359-z

Marini, J. C., Forlino, A., Bächinger, H. P., Bishop, N. J., Byers, P. H., Paepe, A. D., Fassier, F., Fratzl-Zelman, N., Kozloff, K. M., Krakow, D., Montpetit, K., & Semler, O. (2017). Osteogenesis imperfecta. Nature Reviews Disease Primers, 3, 17052. https://doi.org/10.1038/nrdp.2017.52

Morello, R. (2018). Osteogenesis imperfecta and therapeutics. Matrix Biology, 71-72, 294-312. https://doi.org/10.1016/j.matbio.2018.03.010

National Institutes of Health, National Library of Medicine. (2024). Osteogenesis imperfecta. StatPearls. National Center for Biotechnology Information.

Ramzan, K., Alotaibi, M., Huma, R., & Afzal, S. (2021). Detection of a recurrent TMEM38B gene deletion associated with recessive osteogenesis imperfecta. Diagnostics, 11(3), 571. https://doi.org/10.15190/d.2021.3

Shapiro, J. R., & Sponsellor, P. D. (2009). Osteogenesis imperfecta: Questions and answers. Current Opinion in Pediatrics, 21(6), 709-716.

Sillence, D. O., Senn, A., & Danks, D. M. (1979). Genetic heterogeneity in osteogenesis imperfecta. Journal of Medical Genetics, 16(2), 101-116. https://doi.org/10.1136/jmg.16.2.101